cell-cell adhesion factor. CD34 + cells represent approximately 1.15%
(1%-3%) of bone marrow mononuclear cells (BM-MNCs), 0.12%-0.15% of cells in umbilical cord blood, and 0.1% of peripheral blood cells. 5 Recently, several companies have developed equipment for CD34 + cell purification using antibody-coated magnetic beads, avidin-coated beads, or antibody-bound beads. Reinfusion of purified CD34 + cells after high-dose chemotherapy has shown normal and durable engraftment, similar to total peripheral blood transfusion or bone marrow transplant. [6] [7] [8] [9] Endothelial progenitor cells differentiate into endothelial cells in a process referred to as vasculogenesis. 10 Vasculogenesis describes the development of new blood vessels from in situ differentiating endothelial cells, 11 whereas angiogenesis is the process of remodeling and expanding this network. Until recently, vasculogenesis was considered to be restricted to embryogenesis; however, there now exists striking evidence that EPCs also circulate in adult peripheral blood and participate in ongoing neovascularization. 12 Different cytokines and growth factors have a stimulatory effect on these bone-marrow-derived EPCs. Granulocyte macrophage colonystimulating factor (GM-CSF) and vascular endothelial growth factor (VEGF) mobilize EPCs from the bone marrow into the peripheral circulation. 13 Although their contribution to postnatal neovascularization needs to be documented, the expansion and mobilization of EPCs might represent an effective means of augmenting the resident population of ECs. 14 This kind of cell therapy for tissue regeneration in ischemic cardiovascular diseases opens a novel and challenging clinical option in lieu of or in addition to the use of growth factors in gene therapy. 15 Previously, most clinical studies used bone BM-MNCs, [16] [17] [18] [19] peripheral blood mononuclear cells (PBMCs), 20 genes, and cytokines. [21] [22] [23] [24] The present pilot study was initiated to evaluate the feasibility, safety, and efficacy of transplantation of fresh CD34 + cells, which were considered the predominant functional cells for vasculogenesis [25] [26] [27] that had been immunomagnetically isolated from PBMCs. 28 
| MATERIAL S AND ME THODS

| Experimental animals
In all, 36 male BALB/C athymic nude mice, 8-week old and weighing 22.5-27.5 g, were provided and housed by the Experimental Animal
Center of Zhongshan Hospital, Fudan University. This study was approved by the Animal Care and Use Committee of Fudan University.
| Patient demographics
Patients suffering from severe lower extremity arterial ischemia were enrolled in the study. 
| Mobilization of CD34 + cells into the peripheral circulation
To mobilize movement of CD34 + cells from the bone marrow into the peripheral circulation, patients were injected subcutaneously with 300 μg granulocyte colony-stimulating factor(G-CSF) filgrastim) in the morning and 150 μg in the afternoon, for a total daily dose of 5-10 μg/kg, for 5 days. White blood cell test was carried out once daily. Low molecular weight heparin (Clexane, 4000 IU) was injected subcutaneously once daily. Cilostazol (50 mg) was taken orally twice daily. Aspirin (100 mg) was taken once daily.
| Collection of peripheral blood
Peripheral blood mononuclear cells were collected on day 5 of mobilization. A routine blood test was conducted, and 3 hours before collection, patients were injected with 300 μg filgrastim and 5 mg dexamethasone. Blood was collected using a COM.TEC blood cell separator (Fresenius Kabi, Bad Homburg, Germany, http://www.fresenius-kabi.com) at a flow rate of 45-50 mL/min. Circulating blood volume was 10-12 L (2-2.5 cycles). Anticoagulant (sodium citrate) was administered at 1/12 the volume of circulating blood. Calcium gluconate was given to prevent hypocalcemia. Collected blood was transferred to an octopus bag in a large-capacity centrifuge. Sample volumes were adjusted with PBS and 5 g/L human serum albumin, and samples were centrifuged at 1000 rpm for 15 minutes to remove platelet-rich plasma. 
| CD34
| Growth curves
CD34
+ cells (1 × 10 4 ) were seeded in wells of six 24-well plates and cultured in X-XIVO medium, DMEM-H, or X-XIVO until day 9 and DMEM-H thereafter. Medium was changed every 3 days, and cells were passaged once a week. Cells in three wells of each plate were counted each day, and the mean number of cells was determined.
Growth curves were generated for each group of cells. 
| Cell cryopreservation and recovery
| Immunohistochemical staining of CD34 and CD133
Slides seeded with cells were fixed in 4% paraformaldehyde for 20 minutes, rinsed with PBS containing 0.1% bovine serum albumin (BSA), and blocked in PBS containing 1% BSA, 10% donkey serum, and 0.1% Triton X-100 for 45 minutes. Cells were then incubated with PE-conjugated anti-CD34 (or FITC-conjugated anti-CD133) primary antibody diluted 1:100 in PBS containing 20% fetal bovine serum (FBS) at room temperature in the dark for 1-2 hours. Cells were incubated with secondary antibody in a humidified chamber at room temperature in the dark for 1 hours, and incubated with 1 mg/ mL 4′,6-diamidino-2-phenylindole (DAPI) for 5 minutes to counterstain nuclei.
| Induction of limb ischemia and treatment with CD34 + cells
In all, 36 BALB/C nude mice were randomly divided into three groups of 12 mice each. Mice were anesthetized. A 2-cm incision was made from the midpoint of the left groin to the knee, and the femoral nerve and the femoral artery and its branches were exposed. In the CD34 + treatment group and the X-VIVO control group, the superficial femoral artery was ligated and stripped followed by suturing of the skin. In the sham group, skin was sutured without ligation and transection of the artery.
| CD34 + cell transplantation
Seven days after surgery, mice in the CD34 + group were injected with 1 × 10 5 CD34 + cells in 0.1 mL X-VIVO medium in the ischemic muscle tissue of the left limb using a 26 gauge needle. Mice in the X-VIVO control group were injected with 0.1 mL X-VIVO medium alone, and mice in the sham group were injected with 0.1 mL saline.
| Assessment of ischemic injury
One week after surgery and again 2 weeks after CD34 cell transplantation, mice were scored for extent of ischemic injury according to the following scale 29 : 3 points, if the hind limb dragged or showed gangrene; 2 points, if limb dragging was not obvious, but foot lacked plantar flexion, or limb was moderately discolored; 1 point, if tail was pulled, ipsilateral foot showed plantar flexion, or limb was mildly discolored; 0 points if animal appeared no different from a control mouse.
| Immunohistochemistry
Samples of adductor and semimembranosus muscles were collected 2 weeks after CD34 + cell transplantation. Tissues were fixed in 10%
formalin and embedded in paraffin. Sections were treated with anti-CD31 and anti-CD34 antibodies to stain vascular endothelial cells (ECs).
| Real-time PCR analysis of cytokine mRNA levels
Total RNA was extracted from ischemic and control muscle tissue.
RNA purity and concentration were determined, and cDNA was prepared and used in real-time PCR to assess expression of VEGF and bFGF. Primer sequences were VEGF, 5′-GCACATAGAGAGAATGAGCTTCC-3′ (forward) and 3′-CTCCGCTCTGAACAAGGCT-5′ (reverse); bFGF, 5′-GCGACCCACACGTCAAACTA-3′ (forward) and 3′-CCGTCCATCTTCCTTCATAGC-5′ (reverse); and 18S, 5′-CGCCGCTAGAGGTGAAATTCT-3′ (forward) and 3′-CATTCTTGGCAAATGCTTTCG-5′ (reverse).
| CD34 + cell transplantation into patients
Spinal anesthesia was usually used when the lower limb was treated and general anesthesia was used when the limb was treated. Purified CD34 + cells (0.5 mL) were injected into calf muscle at 60 sites and into feet and toes at 20 sites; injection sites were separated by 3 cm.
The total number of cells transplanted was 1 × 10 5 -1 × 10 6 /kg. If the patient developed infected ulcers or gangrene, debridement or amputation was carried out, whereas dry gangrene unaccompanied by infection was treated next time. Cilostazol and aspirin would be taken for life after transplantation.
| Patient follow-up protocol and endpoints
All patients were followed up once monthly for the first 3 months after transplantation, once every 2 months at 4-12 months after transplantation, and every 6 months thereafter. Additionally, a follow-up phone call was made every week during the first month to identify when pain the rest began to subside. Safety endpoints 
| Statistical analysis
The Kaplan-Meier method was used to estimate the rate of survival without major amputation at 6 months, and the Greenwood method was used to calculate the corresponding 95% confidence interval. One-way ANOVA, Wilcoxon signed-rank test, and MannWhitney U test were used to compare groups. Quantitative indicators, such as cell viability, ABI, TcPO2, PPFWT, and WFPRSS, were expressed as mean ± SD, and analyzed via t test. P value < .05 was considered statistically significant. Statistical analysis was carried out using SPSS l6 software. 
| Visualization and analysis of cell proliferation and migration
Continuous live-cell imaging using Cell-IQ showed that the suspended cells rapidly migrated to the center of the culture dish (Figure 2A-F) . Cell division was observed, and the average time between divisions was calculated to be 90 minutes (Figure 3 ).
| CD34 + cell growth under different culture conditions
Growth curves for cultures of suspended CD34 + cells grown in X-VIVO or DMEM-H and for adherent cells grown in X-VIVO until day 9 and thereafter in DMEM-H are shown in Figure 4 . In all groups, we found that days 1-3 were the incubation period, days 5-7 were the logarithmic growth phase and, after the logarithmic phase, cell growth gradually plateaued at 8-9 days. The number of cells grown exclusively in X-VIVO or DMEM-H was not maintained at a constant level on days 9-14, and the cells died 
gradually. However, after DMEM-H replaced X-VIVO on day 9 in the third group of cells, these cells entered another phase of logarithmic growth (Figure 4 ).
| CD34 and CD133 expression
Adherent primary (P1) and fourth passage (P4) CD34 + cells were positive for expression of the cell surface markers CD34 and CD133 ( Figure 5 ).
| Cryopreservation and recovery of CD34 + cells
CD34 + cells were stored at −80°C for 1 year in medium containing 10% Cryostor or 10% DMSO. The viability of recovered cells was greater for cells stored in Cryostor (89.0% ± 2.58) than in DMSO (84.9% ± 3.28) (P = .006) (Figure 6 ).
| Ischemic injury score and prognosis
The ischemic injury scores and prognosis for the three groups of mice before and after transplantation are shown in Table 1 and Figure 7 .
Before transplantation, both the CD34 + and X-VIVO groups were significantly different from the sham group (P = .000), indicating that the model of hind limb ischemia was successful. The injury scores of the CD34 + group before and after transplantation were significantly different (P = .020), illustrating that limb ischemia was improved by CD34 + cell transplantation. The X-VIVO group improved after transplantation compared to before transplantation, but the difference was not significant (P = 0.083). There was also no significant difference between the CD34 + and X-VIVO groups after transplantation (P = 0.343).
| Real-time PCR analysis of cytokine mRNAs
mRNA expression levels of the angiogenic cytokines VEGF and bFGF were significantly higher in the CD34 + group than in the X-VIVO and sham groups (P < .05) (Figure 8 ). These data suggest that CD34 + cells may upregulate VEGF and bFGF expression, thus promoting angiogenesis through paracrine effects.
| Immunohistochemical staining of CD34 and CD31 in ischemic muscle
Vascular endothelial cells in sections of muscle taken from the three groups of mice showed positive staining with anti-CD31 and anti-CD34 antibodies ( Figure 9 ). Staining of new capillaries was most extensive in the CD34 + group. New capillaries were rarely observed, but some larger vessels were seen in the sham group, whereas both new capillaries and larger vessels were rare in the X-VIVO group. 
| Patient follow-up
Pain at rest was apparently relieved within 1 month of CD34 + cell transplantation in 19 of the 25 patients. The mean time to pain relief was 3 ± 1 weeks (range, 2-8 weeks). WFPRSS decreased from 7 ± 2 to 3 ± 3 (P < .001) and 1 ± 2 (P < .001) at 1 and 2 months, respectively, and there was also a significant difference between 1 and 2 postoperative months (P = .02). In all, 12 cases were eligible for a test of PPFWT, which increased markedly from 5 ± 3 minutes to 12 ± 6 minutes (P < .001) and 19 ± 5 minutes (P < .001) at 3 and 6 months, respectively. ABI was considerably elevated from 0.44 ± 0.20 to 0.62 ± 0.17 (P = .004) and 0.66 ± 0.14 (P < .001) at 3 and 6 months, respectively, whereas the difference between 3 and 6 postoperative months was not statistically significant (P = .19). TcPO2 was significantly improved from 26 ± 11 mm Hg to 42 ± 11 mm Hg (P < .001) and 56 ± 12 mm Hg (P < .001) at 3 and 6 months, respectively. Also, the improvement from 3 to 6 months was statistically significant (P = .0001) ( Table 2) . Of the 16 cases with an ulcer, the ulcer healed within 5 ± 4 months (range, 2-14 months) in 11 patients (69%).
In the four cases with an unhealed ulcer, two ASO cases received above-the-knee amputation within 3 post-transplantation months.
The other two cases were still receiving wound care; one case had an Another ASO case underwent an above-the-knee amputation at 1 month because of progressive pain at rest. The Kaplan-Meier estimate of the rate of survival without major amputation at 16 months was 84% (95% confidence interval, 0.63-0.94).
| Safety evaluation
Mobilization-induced events, such as nausea, lower back pain, and low-grade fever, occurred in 12 cases and were spontaneously relieved within 2-3 days. Numbness of the lips observed in 13 patients during apheresis disappeared shortly after oral administration of F I G U R E 7 Hindlimb ischemia of CD34 nude mice. The typical hindlimb ischemia and healing in the CD34 group were observed at 3d, 7d, 10d, 14d, and 21d after modeling. It can be found that CD34 + cell transplantation has favorable therapeutic effects on hindlimb ulcers in nude mice, but poor effects on acute gangrene 
| D ISCUSS I ON
Many studies agree that cells initially CD34 
Items Before 3 months after P value 6 months after P value PPFWT (min) 5 ± 3 12 ± 6 P < .001 19 ± 5 P < .001 ABI 0.44 ± 0.20 0.62 ± 0.17 P = .004 0.66 ± 0.14 P < .001
TcPO2 (mm Hg) 26 ± 11 42 ± 11 P < .001 56 ± 12 P < .001
ABI, Ankle brachial index; PPFWT, peak pain-free walking time; TcPO 2 , transcutaneous partial oxygen pressure.
TA B L E 2
The follow-up items before and after transplantation cells were EPCs. We cryopreserved the suspended cells and recovered them after 1 year of storage, with 89% viability. This provided theoretic support for transplantation of cells after in vitro culture.
During live-cell image analysis using Cell-IQ, we observed the interesting phenomenon that the majority of CD34 + cells migrated to the center of the culture dish, where they were visible to the naked eye because of high density. This may be an indication that EPCs can migrate to the site of an injury in response to a specific signal. We reviewed the literature and found no relevant reports. Is there some factor that drives cells to the center? Further research is needed to identify the signaling pathways and underlying mechanisms involved in this phenomenon.
It has been proposed that there are two mechanisms of vasculogenesis. [36] [37] [38] One is that EPCs differentiate and develop directly through migration and homing to damaged blood vessels. The other is that EPCs secrete cytokines, such as VEGF, bFGF, and angiopoietin-1 (ang-1), thus promoting vasculogenesis in ischemic tissues by a paracrine route. 39 Generally, bFGF promotes the growth of new vessels early in vasculogenesis, and VEGF then performs the primary role of sustaining vasculogenesis. 40 Ang-1 and VEGF perform complementary functions in vasculogenesis and angiogenesis. VEGF promotes endothelial cell proliferation and migration to establish a uniform vascular network, and Ang-1 remodels vessels to complete the mature vascular network with normal function in later stages. 41 Some studies also found that ischemic limb perfusion can be significantly increased and damage repair improved by perfusing immunodeficient mice with EPCs, but only a small number of EPCs integrated into the new capillaries. [42] [43] [44] [45] This phenomenon illustrates that EPCs may release angiogenic factors through paracrine signaling.
In this study, we found that levels of VEGF and bFGF mRNAs into EPCs in an ischemic setting. 47, 48 In our study, 25 patients were not eligible for bypass surgery or endovascular therapy and who had undergone ineffective drug treatment for more than 3 months, but their ABI, PPFWT, TcPO2, and WFPRSC improved significantly after transplantation of purified CD34 + cells. It was noted that results with all three ASO cases were unsatisfactory, suggesting that CD34 + cell transplantation might be less effective in patients with ASO than in those with TAO or arteritis.
A similar finding was reported after transplantation of BM-MNCs or PB-MNCs, with overall efficacy rates of 50% and 80% in ASO and TAO patients, respectively. 17, 18, 49 The proposed causes were (1) factors causing endothelial dysfunction or depletion, such as aging, diabetes, and hypercholesterolemia, were much more common in ASO patients;
and (2) plasma levels of angiogenic cytokines, such as VEGF, a critical factor in vasculogenesis and angiogenesis, were attenuated in older patients. [50] [51] [52] [53] In summary, transplantation of purified CD34 + cells appears to be feasible, safe, and effective in treatment of no-option CLI, particularly in younger patients with TAO or collagen diseases.
In short, there are many properties of CD34 cells that still must be explored, and elucidation of the mechanism of vasculogenesis requires further research. Further clinical research, employing a greater number of patients and longer follow-up periods, are necessary.
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